Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 2 Study of Necitumumab Plus Carboplatin/Paclitaxel in Stage IV Squamous NSCLC
2012-003214-13Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of necitumumab in Pulmonary squamous cell carcinoma (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Objective Response Rate per Arm. Started Nov 2012; status: completed.
02
Drugs
necitumumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2012-003214-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003214-13.